iinews – Der mobile Newsdienst

« | »

Cell Counting Market Worth to USD 12.31 billion by 2023


According to MarketsandMarkets Latest Report \”Cell Counting Market by Product (Instruments (Spectrophotometer, Cell Counter, Hemocytometer, Flow Cytometer, Hematology Analyzer), Consumables (Reagent, Assay Kits, Microplate)), End User (Pharmaceutical, Hospital, Research) - Global Forecast to 2023\”

The overall cell counting market is expected to grow from USD 8.29 billion in 2017 to USD 12.31 billion by 2023, at a CAGR of 6.8% from 2018 to 2023.

The cell counting market is expanding with the emergence of new technologies and increasing applications areas. These instruments are being used in various research, clinical & diagnostic, and industrial applications

To know about the assumptions considered for the study, download the pdf brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157450728

Many life science companies are under pressure to maintain their existing profit margins and improve them in the future while facing enormous pressure to cut prices. This has led to dramatic shifts in the business models of some manufacturers in this industry. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

The cell counting market has been segmented, on the basis of product, into consumables and instruments. The market for consumables is expected to grow at the highest CAGR between 2018 and 2023. On the other hand, among all the instruments, spectrophotometers are most widely used for cell analysis. The high adoption of these instruments is contributing to the rapid growth of the market.

The prominent players in the global cell counting market are Danaher Corporation (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad Laboratories (US), GE Healthcare (US), PerkinElmer (US), Agilent Technologies (US), BioTek Instruments (US), Tecan Group (Switzerland), Roche Diagnostics (Switzerland), Sysmex Corporation (Japan), HORIBA, Ltd. (Japan), Abbott Laboratories (US), and Siemens Healthineers (Germany).

Major Market Developments

In May 2018, Danaher Corporation launched the DxH 900 hematology analyzer, giving mid- to high-volume clinical laboratories the ability to perform complete blood count and white blood cell differential tests with minimal repeats.

In April 2018, BioTek Instruments collaborated with Agilent Technologies to create a new integrated metabolic analysis and imaging platform by integrating Agilent Seahorse XFe96/XFe24 Analyzers with the BioTek Cytation 1 Cell Imaging Multi-Mode Reader to improve assay workflow.

In February 2018, Merck invested USD 19.51 million (EUR 16.6 million) in its new manufacturing and distribution centre for the Life Science business located in Mumbai to be completed in 2019. This will strengthen the company\’\’\’\’s overall manufacturing and supply chain infrastructure. Read More

Posted by on 19. Juni 2019.


Categories: Bilder, Vermischtes

0 Responses

You must be logged in to post a comment.

« | »

Neue Beiträge